Google announced that a large foundation model in its Gemma family—Cell2Sentence‑Scale—proposed and validated a novel drug combination for cancer, marking an AI‑driven discovery advance. The firm reported that the 27‑billion‑parameter model suggested a combination and that subsequent validation steps supported the finding. This announcement signals growing confidence from major tech players that large language and multimodal models can accelerate hypothesis generation and candidate selection in biomedical research. Foundation models are large pretrained AI systems that can be fine‑tuned for domain tasks such as molecular design and biomedical literature synthesis. While the disclosure is a milestone, independent peer‑review and reproducibility will determine the long‑term scientific and commercial impact; sponsors and investors will watch validation details and translational timelines closely.